PTGX同业对比
PTGX 与SPDR S&P Biotech ETF 持仓的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:XBI 前十大持仓| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PTGX本股 | $8.7B#5 | 131.2x#1 | 10.4x#8 | 190.0x#5 | -89.4%#8 | -147.3%#14 | -343.6%#4 | -15.5%#6 | -36.7%#2 | — | — | — |
| MRNA | $96.4B#1 | — | 14.3x#11 | 49.6x#3 | -39.9%#6 | 20.8%#5 | -158.1%#3 | -41.7%#12 | -54.6%#4 | — | 925.6%#1 | — |
| TWST | $7.6B#7 | — | 17.0x#13 | 20.1x#1 | 20.3%#4 | 62.8%#1 | -36.2%#1 | -17.4%#8 | -41.4%#3 | — | — | — |
| ORKA | $6.4B#10 | — | 5.7x#6 | — | — | -25.9%#7 | — | -9.5%#4 | — | — | — | — |
| KYMR | $10.9B#3 | — | 6.8x#7 | 279.2x#6 | -16.7%#5 | 39.1%#2 | -891.1%#6 | 19.3%#1 | — | — | — | — |
| VKTX | $3.3B#14 | — | 5.6x#5 | — | — | -227.1%#15 | — | -61.1%#14 | — | — | — | — |
| PRAX | $7.3B#8 | — | 5.5x#3 | — | -100.0%#9 | -65.6%#10 | — | -22.6%#10 | — | — | — | — |
| ERAS | $4.6B#13 | — | 12.7x#10 | — | — | 23.0%#4 | — | -34.4%#11 | — | — | — | — |
| RVMD | $38.5B#2 | — | 16.0x#12 | — | — | -88.5%#12 | — | -47.1%#13 | — | — | — | — |
| RYTM | $7.3B#9 | — | 82.9x#14 | 38.4x#2 | 45.8%#3 | 24.6%#3 | -101.2%#2 | -0.2%#3 | -127.5%#5 | — | — | — |
| CGON | $5.7B#11 | — | 5.6x#4 | 1420.7x#7 | 254.7%#2 | -82.9%#11 | -4722.1%#7 | -15.6%#7 | -18.8%#1 | — | 70.6%#2 | — |
| SLS | $1.6B#15 | — | 11.5x#9 | — | -100.0%#9 | 13.0%#6 | — | -19.5%#9 | — | — | — | — |
| PCVX | $9.8B#4 | — | 3.9x#2 | — | — | -65.2%#9 | — | -0.0%#2 | — | — | — | — |
| DNTH | $4.7B#12 | — | 3.8x#1 | 2301.2x#8 | -67.3%#7 | -91.1%#13 | -8739.3%#8 | -13.1%#5 | — | — | — | — |
| CYTK | $7.8B#6 | — | — | 88.3x#4 | 376.6%#1 | -33.2%#8 | -695.4%#5 | — | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-06。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议